Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Fair Value Measurement - Additional Information (Detail)

Fair Value Measurement - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended
	Aug. 12, 2014	Sep. 30, 2014	Dec. 31, 2014	Mar. 17, 2014	Dec. 31, 2013	Apr. 18, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investments				$ 250,000us-gaap_EquityMethodInvestments
Equity Method Investment, Ownership Percentage				35.00%
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases	50,000		3,218,000
Fair Value, Assets Measured on Recurring Basis, Change in Unrealized Gain (Loss)	293,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net	293,000	293,000
Trading Securities			20,002,000us-gaap_TradingSecurities
Fair Value Assumptions, Risk Free Interest Rate			0.10%
Fair Value Assumptions, Expected Volatility Rate			9.30%
Share Price			$ 2.93us-gaap_SharePrice
Fair Value Assumptions, Exercise Price			$ 11.50
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease)			1,200,000
Investment Owned, at Fair Value			3,900,000us-gaap_InvestmentOwnedAtFairValue
Working Capital			500,000cndo_WorkingCapital
Redeemable warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			$ 0.18
Non Redeemable warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			$ 0.30
Binomial Lattice Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			1.68%
Fair Value Assumptions, Weighted Average Volatility Rate			20.70%
Fair Value Assumptions, Exercise Price			$ 11.50
US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities			20,000,000		20,000,000
Common Stock Subject to Mandatory Redemption [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net Assets			38,000,000
325412 Pharmaceutical Preparation Manufacturing
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Rights			265,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		1,100,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned		25,000
Proceeds from Issuance Initial Public Offering			42,900,000
Business Combination, Consideration Transferred			2,700,000
Business Acquisition, Share Price			$ 10.00
Stock Purchased Under Initial Public Offering			one-tenth of a ordinary share
Expiration Period Of Warrants			five years
Common Stock, Voting Rights			one-half of an ordinary share
Employee Stock Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term Investments			300,000
Equity Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term Investments						243,000
Private Units [Member] \| Ghaidarov Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price			$ 2.99
Argus Neurooptics Llc [Member] \| Class A Preferred Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares Received Under Purchase Agreement				13,409,962
Percentage Of Shares Received Under Purchase Agreement				83.00%
Preferred Units, Issued				16,091,954
Hercules Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable					$ 13,700,000